Company: BLLN
Filing Date: 2025-10-17
Form Type: S-1/A
Source: 0001193125-25-242632
Chunk: 153

Company: BillionToOne, Inc.
Filing Date: 2025-10-17
Form: S-1/A
Chunk 153
---
 the United States alone. Half of this addressable market includes early detection, an area in which we have not yet begun specific product development or commercial sales, but we believe will be strongly enabled by our existing technology platform.

| 28 |     | This estimate is based on a survey of over 100 OB/GYNs and MFMs conducted on our behalf in 2023 about their use of carrier screening panels. In response to a survey question about which panel sizes OB/GYNs and MFMs use                              
 for carrier screening, 35% of respondents indicated they use a panel covering 2-5 conditions, and 25% of respondents indicated they use a panel covering 6-15 conditions. Therefore, based on the survey responses, we estimate the 14-gene UNITY panel 
 could potentially expand the serviceable addressable market for UNITY by 70% compared to the 5-gene panel.                                                                                                                                              |

101

We believe our smNGS platform will drive our continued and rapid growth in $100B markets. $1B1 Carrier Screening Launched 2019 PRENATAL $1.5B1 Aneuploidy Testing Launched 2020 $6B2 Therapy Selection Launched 2023 ONCOLOGY $15B+3 Therapy Monitoring Launched 2023 $30B+4 Minimal Residual Disease Planned $50B+5 Early Detection Potential

| (1) |     | Estimated $2.5 billion prenatal market assumes two tests per pregnancy (per ACOG guidelines, which also support the use of NIPT for all pregnancies regardless of maternal age or prior risk), over 3.5 million 
 births annually in the United States (per publicly available 2023 CDC data), and an ASP of over $400 per test (consistent with our historical ASP).                                                             |

| (2) |     | Estimated $6 billion therapy selection market assumes 800,000 late-stage cancer patients are diagnosed every year (based on (i) 2,000,000 new cancer cases, excluding non-melanoma skin cancers, in the United States                               
 (per publicly available 2025 data from the American Cancer Society) and (ii) approximately 40% of cancers detected are late-stage (per publicly available 2025 data from the CDC)), two tests per patient (consistent with our internal user data), 
 and an ASP of $4,000 per test (based on industry benchmarks ranging from approximately $3,000 to over $5,000 per test).